Astellas: Large-scale gene therapy plant major driver in $3bn Audentes deal
Gaining clinical and commercial manufacturing capabilities through the acquisition of Audentes will reduce reliance on third-party manufacturers in the gene therapy space, Astellas says. Japan’s Astellas increased its presence in the gene therapy space yesterday by announcing plans to buy San F ...
Zelluna Immunotherapy and Glycostem Therapeutics have teamed up to develop TCR cell therapies for cancers, including hard-to-treat solid tumors. ...
Polyplus-transfection SA has expanded its reagent portfolio, citing the growing number of candidate cell and gene therapies nearing commercializa ...
Novartis has opened a CHF 90 million ($91 million) manufacturing site in Stein, Switzerland to support its cell and gene portfolio.
In August ...
Cell and viral vector backlogs reduce patient access to next-generation medicines and slow R&D says the consortium behind a $50 million innov ...
Recent Tweets
-
RT @PBOAssoc: Differences Put Aside As ICH Finalizes Guide On Post Approval Changes :: Pink Sheet https://t.co/62KaQtmBV6
2 days ago
-
RT @frankvinluan: Fresh off two deals with Novartis earlier this year, @IFMThera reloads w/ $55.5M to launch a new subsidiary & incub… https://t.co/TjFPZNJnMH
2 days ago
-
RT @Dan5tanton: UK #cellandgene therapy firms are worried a shortage of skilled manufacturing staff will slow growth with some conc… https://t.co/39yI5o1nrZ
2 days ago
-
RT @Dan5tanton: CBMG hopes to leverage R&D done in #China to expedite trials in US as it establishes facilities in MD, but is it l… https://t.co/89lvL3oerf
1 week ago
Trending
Upstream Processing
eBook: Addressing Production Complexities — Strategies for Working with Difficult and Susceptible Proteins
BPI White Papers
Why Characterizing Protein Stability Matters For Drug Development
2019
BioProcess International 2019 Event Report
BPI White Papers
Ten important lessons the cell and gene therapy industry can take from the bioprocessing industry